Brain metastases (BM) are rare in colorectal cancer (CRC) and are associated with a dismal prognosis. This work aims to report the rate of BM in CRC patients treated in a single institution, along with survival and prognostic factors.
Methods:
Medical charts for patients with histologically proven CRC were retrospectively reviewed.
Results:
A total of 538 patients were identified, of whom 33% developed any metastatic disease and 4.4% presented BM. Lung was the most frequently associated metastatic site (in 68% of the cases). The only factor independently associated with BM development was the presence of metastatic disease at the time of initial presentation. The median duration from initial diagnosis to BM development was 38.6 months (SD 29.1 months). Median survival after BM development was 62 days (95% confidence interval [CI] 56–68). Patients diagnosed with BM within 1 year of cancer diagnosis responded significantly better to treatment than those who acquired BM later, with a median survival after BM diagnosis of 261 days versus 61 days, respectively (p = .002). Patients with BM who received antiangiogenic therapy had an improved median survival compared to those who did not (151 days vs 59 days, p = 0.02; hazard ratio for death 0.29 [95% CI 0.09–0.94]).
Conclusion:
CRC with BM is an aggressive disease resistant to standard treatment and is associated with poor outcomes. Adding antiangiogenic therapy might be of value for those patients. Patients with BM developing early in the disease course might respond better to treatment.
PatelPDeP.Trends in colorectal cancer incidence and related lifestyle risk factors in 15–49-year-olds in Canada, 1969–2010. Cancer Epidemiol2016; 42: 90–100.
2.
Mengual-BallesterMPellicer-FrancoEValero-NavarroG, et al. Increased survival and decreased recurrence in colorectal cancer patients diagnosed in a screening programme. Cancer Epidemiol2016; 43: 70–75.
3.
Azimafoussé AssogbaGFJezewski-SerraDLastierD, et al. Impact of subsequent screening episodes on the positive predictive value for advanced neoplasia and on the distribution of anatomic subsites of colorectal cancer: a population-based study on behalf of the French colorectal cancer screening program. Cancer Epidemiol2015; 39: 964–971.
4.
RahmathullaGTomsSAWeilRJ.The molecular biology of brain metastasis. J Oncol2012; 2012: 723541.
5.
SvokosKASalhiaBTomsSA.Molecular biology of brain metastasis. Int J Mol Sci2014; 15: 9519–9530.
6.
FabiAFeliciAMetroG, et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res CR2011; 30: 10.
7.
DamiensKAyoubJPMLemieuxB, et al. Clinical features and course of brain metastases in colorectal cancer: an experience from a single institution. Curr Oncol Tor Ont2012; 19: 254–258.
8.
ZangY-WGuX-DXiangJ-B, et al. Brain metastases from colorectal cancer: microenvironment and molecular mechanisms. Int J Mol Sci2012; 13: 15784–15800.
9.
TanriverdiOKaytan-SaglamEUlgerS, et al. The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG). Med Oncol Northwood Lond Engl2014; 31: 152.
10.
HugenNvan de VeldeCJHde WiltJHW, et al. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol Off J Eur Soc Med Oncol2014; 25: 651–657.
11.
CanteDGirelliGLa PortaMR, et al. Late brain metastases from colorectal cancer a case report and review of the literature. Tumori2005; 91: 280–282.
12.
UbinkIJongenJMJNijkampMW, et al. Surgical and oncologic outcomes after major liver surgery and extended hemihepatectomy for colorectal liver metastases. Clin Colorectal Cancer2016; 15: e193–e198.
13.
BotrelTEAClark LG deOPaladiniL, et al. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer2016; 16: 677.
14.
ChuCNavalkissoorSGillmoreR.Neurological symptoms from a brain metastasis as the first presentation of colorectal cancer. BMJ Case Rep2015; 2015: 210422.
15.
JiangX-BYangQ-YSaiK, et al. Brain metastases from colorectal carcinoma: a description of 60 cases in a single Chinese cancer center. Tumour Biol J Int Soc Oncodevelopmental Biol Med2011; 32: 1249–1256.
16.
LinLZhaoC-HGeF-J, et al. Patients with brain metastases derived from gastrointestinal cancer: clinical characteristics and prognostic factors. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex2016; 18: 93–98.
17.
LévyCAllouacheDLacroixJ, et al. REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. Ann Oncol Off J Eur Soc Med Oncol2015; 26: 2359.
18.
LouESperdutoPW.Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach?Ann Transl Med2016; 4: 36.
19.
FinkelmeierFYouS-JWaidmannO, et al. Bevacizumab in combination with chemotherapy for colorectal brain metastasis. J Gastrointest Cancer2016; 47: 82–88.
20.
PietrantonioFAprileGRimassaL, et al. A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. Radiother Oncol2015; 117: 315–21.
21.
ChristensenTDSpindlerK-LGPalshofJA, et al. Systematic review: brain metastases from colorectal cancer: incidence and patient characteristics. BMC Cancer2016; 16: 260.
22.
TempleDFLedesmaEJMittelmanA.Cerebral metastases: from adenocarcinoma of the colon and rectum. NY State J Med1982; 82: 1812–1814.
23.
RamakrishnaRRostomilyR.Seed, soil, and beyond: the basic biology of brain metastasis. Surg Neurol Int2013; 4: S256–264.
24.
HanahanDWeinbergRA.Hallmarks of cancer: the next generation. Cell2011; 144: 646–674.
25.
BosPDZhangXH-FNadalC, et al. Genes that mediate breast cancer metastasis to the brain. Nature2009; 459: 1005–1009.
26.
AlsidawiSMalekEDriscollJJ.MicroRNAs in brain metastases: potential role as diagnostics and therapeutics. Int J Mol Sci2014; 15: 10508–10526.
27.
NayakLLeeEQWenPY.Epidemiology of brain metastases. Curr Oncol Rep2012; 14: 48–54.
28.
GoPHKlaassenZMeadowsMC, et al. Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer2011; 117: 3630–3640.
29.
LeoneJPLeoneBA.Breast cancer brain metastases: the last frontier. Exp Hematol Oncol2015; 4: 33.
30.
SundermeyerMLMeropolNJRogatkoA, et al. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer2005; 5: 108–113.
31.
RostamiRMittalSRostamiP, et al. Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol2016; 127: 407–414.
32.
Barnholtz-SloanJSSloanAEDavisFG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol Off J Am Soc Clin Oncol2004; 22: 2865–2872.
33.
ZulligLLSmithVAJacksonGL, et al. Colorectal cancer statistics From the Veterans Affairs Central Cancer Registry. Clin Colorectal Cancer2016; 15: e199–e204.
34.
QiuMHuJYangD, et al. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget2015; 6: 38658–38666.
35.
ShabihkhaniMYuSSYangD, et al. Metastatic colorectal cancer in Hispanics: treatment outcomes in a treated population. Clin Colorectal Cancer2016; 15: e221–e227.
36.
ParkJHKimMJParkSC, et al. Difference in time to locoregional recurrence between patients with right-sided and left-sided colon cancers. Dis Colon Rectum2015; 58: 831–837.
37.
BenedixFKubeRMeyerF, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum2010; 53: 57–64.
38.
SunakawaYIchikawaWTsujiA, et al. Prognostic impact of primary tumor location on survival time in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05/06. J Clin Oncol2016; 34: suppl 613.
39.
FarnellGFBucknerJCCascinoTL, et al. Brain metastases from colorectal carcinoma. The long term survivors. Cancer1996; 78: 711–716.
40.
TokoroTOkunoKHidaJ, et al. Prognostic factors for patients with advanced colorectal cancer and symptomatic brain metastases. Clin Colorectal Cancer2014; 13: 226–231.
41.
GuptaGPNguyenDXChiangAC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature2007; 446: 765–770.
42.
LipsycMYaegerR.Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol2015; 6: 645–649.
43.
KhuntiaDBrownPLiJMehtaMP.Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol Off J Am Soc Clin Oncol2006; 24: 1295–1304.
44.
PatchellRATibbsPAWalshJW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med1990; 322: 494–500.
45.
PatchellRATibbsPARegineWF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA1998; 280: 1485–1489.
46.
KocherMSoffiettiRAbaciogluU, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol2011;29:134–41
47.
SahgalAAoyamaHKocherM, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys2015; 91: 710–717.
48.
PeiXLiuYSunL, et al. Outcome of molecular targeted agents plus chemotherapy for second-line therapy of metastatic colorectal cancer: a meta-analysis of randomized trials. Clin Colorectal Cancer2016; 15: e149–e156.
49.
AprileGCasagrandeMDe MaglioG, et al. Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. Future Oncol2017;13:135–144.
50.
El-DeiryWSVijayvergiaNXiuJ, et al. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther2015; 16: 1726–1737.
